When the initial visual-acuity letter score was 78 to 69 ( equivalent to approximately 20/32 to 20/40 ) ( 51 % of participants ) , the mean improvement was 8.0 with aflibercept , 7.5 with bevacizumab , and 8.3 with ranibizumab ( P > 0.50 for each pairwise comparison ) .